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Abstract
Objective Dosimetric comparison of HIPO (hybrid inverse planning optimisation) and IPSA (inverse planning simulated
annealing) inverse and forward optimisation (FO) methods in brachytherapy (BT) of breast, cervical and prostate cancer.
Methods At our institute 38 breast, 47 cervical and 50 prostate cancer patients treated with image-guided interstitial
high-dose-rate BT were selected. Treatment plans were created using HIPO and IPSA inverse optimisation methods as
well as FO. The dose–volume parameters of different treatment plans were compared with Friedman ANOVA and the LSD
post-hoc test.
Results IPSA creates less dose coverage to the target volume than HIPO or FO: V100 was 91.7%, 91% and 91.9% for
HIPO, IPSA and FO plans (p= 0.1784) in breast BT; 90.4%, 89.2% and 91% (p= 0.0045) in cervical BT; and 97.1%,
96.2% and 97.7% (p= 0.0005) in prostate BT, respectively. HIPO results in more conformal plans: COIN was 0.72, 0.71
and 0.69 (p= 0.0306) in breast BT; 0.6, 0.47 and 0.58 (p< 0.001) in cervical BT; and 0.8, 0.7 and 0.7 (p< 0.001) in prostate
BT, respectively. In breast BT, dose to the skin and lung was smaller with HIPO and FO than with IPSA. In cervical BT,
dose to the rectum, sigmoid and bowel was larger using IPSA than with HIPO or FO. In prostate BT, dose to the urethra
was higher and the rectal dose was smaller using FO than with inverse methods.
Conclusion In interstitial breast and prostate BT, HIPO results in comparable dose–volume parameters to FO, but HIPO
plans are more conformal. In cervical BT, HIPO produces dosimetrically acceptable plans only when more needles are
used. The dosimetric quality of IPSA plans is suboptimal and results in unnecessary larger active lengths.
Keywords Inverse optimisation algorythms · HIPO hybrid inverse planning optimisation · IPSA inverse planning
simulated annealing · Breast brachytherapy · Prostate brachytherapy · Cervical brachytherapy
Dosimetrischer Vergleich von inversen Optimierungsmethoden versus Vorwärtsoptimierungbei
Hochdosis-Brachytherapie des Mamma-, Zervix- und Prostatakarzinoms
Zusammenfassung
Ziel Es erfolgte ein dosimetrischer Vergleich von inversen und Vorwärtsoptimierungsmethoden (FO) aus dem Bereich
HIPO („hybrid inverse planning optimization“) und IPSA („inverse planning simulated annealing“) in der Brachytherapie
(BT) des Mamma-, Zervix- und Prostatakarzinoms.
Methoden In die Studie wurden 38 Mamma-, 47 Zervix- und 50 Prostatakarzinompatienten aufgenommen, die mit
bildgesteuerter interstitieller hochdosierter BT behandelt worden waren. Behandlungspläne wurden mittels inversen sowie
Vorwärtsoptimierungsmethoden aus dem Bereich HIPO und IPSA erstellt. Die Dosisvolumenparameter der verschiedenen
Behandlungspläne wurden durch Friedman-ANOVA („analysis of variance“) und auf die LSD („least significant difference“)
bezogene Post-hoc-Tests miteinander verglichen.
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Ergebnisse Bei IPSA wird die Zielvolumenabdeckung durch den Einsatz geringerer Dosis im Vergleich zu HIPO oder FO
erreicht; V100 war 91,7%, 91% und 91,9% für HIPO-, IPSA- und FO-Pläne (p= 0,1784) bei Mamma-BT; 90,4%, 89,2%
und 91% (p= 0,0045) bei Zervix-BT sowie 97,1%, 96,2% und 97,7% (p= 0,0005) bei Prostata-BT. Durch HIPO entstehen
gleichmäßigere Pläne, der COIN („conformal index“) betrug 0,72; 0,71 und 0,69 (p= 0,0306) bei Mamma-BT; 0,6; 0,47
und 0,58 (p< 0,001) bei Zervix-BT sowie 0,8; 0,7 und 0,7 (p< 0,001) für Prostata-BT. Bei Mamma-BT war die erfasste
Dosis in Haut und Lungen mit HIPO und FO niedriger als mit IPSA. Im Rahmen der Zervix-BT war die Dosis in Rektum,
Sigma und Darm bei Nutzung von IPSA erhöht im Vergleich zu HIPO oder FO. Bei FO-Anwendungen war die Dosis bei
Prostata-BT im Vergleich zu den inversen Methoden an der Urethra erhöht, die Rektaldosis dagegen erniedrigt.
Schlussfolgerung Bei der interstitiellen Mamma- und Prostata-BT erreicht HIPO vergleichbare Dosisvolumen-Parameter-
werte wie FO, die HIPO-Pläne sind jedoch deutlich konformaler. Bei Zervix-BT generiert HIPO dosimetrisch akzeptable
Pläne nur bei Verwendung von mehreren Nadeln. Die dosimetrische Qualität von IPSA-Plänen ist suboptimal und führt zu
unnötiger zusätzlicher Bestrahlung.
Schlüsselwörter Inverse Optimierung algorithmus · HIPO hybrid inverse planning optimisation · IPSA inverse planning
simulated annealing · Mamma-Brachytherapie · Prostata-Brachytherapie · Zervix-Brachytherapie
Introduction
In spite of some early publications on inverse optimisa-
tion in brachytherapy (BT) [1, 2], inverse dose planning
has played a significant role in external beam radiotherapy
(EBRT) treatment planning since 2000 [3]. In brachyther-
apy these methods have become widespread in the past
decade [4]. Beside the reproducibility of the plans, their
practical advantage is reduced planning time. However, it
needs the accurate setup of the initial preset and it is ben-
eficial only if sufficient degrees of freedom are available
for the algorithm. Therefore, inverse optimisation works
only for interstitial BT treatments, where a large number
of needles and source positions are available. Although,
the planning time is shorter than with forward optimisation
methods, more volumes (i.e. organs at risk) are generally
needed. For example, automatic skin contouring is appro-
priate for forward optimisation (FO) in interstitial breast
BT, but a special 5mm thick skin shell is needed for inverse
methods. Even though inverse methods are currently gener-
ally used in several types of interstitial BT, only a few stud-
ies with a small number of patients have been conducted
on this [5–11]. Comprehensive dosimetric evaluation and
comparison with the forward method are still awaited.
Several inverse methods were developed during the past
decade, but only two are applied widely. Hybrid inverse
planning optimisation (HIPO) is a heuristic, hybrid de-
terministic stochastic dose–volume-based inverse optimi-
sation method [12]. The stochastic algorithm, called simu-
lated annealing, searches the optimal catheter distributions
for a given set of dose objectives. The deterministic algo-
rithm, called dose–volume histogram-based optimisation,
optimizes 3D dose distribution quickly by moving straight
downhill once it is in the advantageous region of the search
space given by the stochastic algorithm. For optimisation of
the dwell times of the radioactive source, the limited-mem-
ory Broyden–Fletcher–Goldfarb–Shanno (L-BFGS) quasi-
Newtonian algorithm is used. The given dose–volume con-
straints are reached at the same time with the minimalisation
of several cost functions.
Inverse planning simulated annealing (IPSA) is a heuris-
tic stochastic anatomy-based inverse optimisation method
[13]. It is determined by the cost function, which repre-
sents the dose prescription and constraints. Since it was
implemented for low-dose-rate seed prostate treatments, it
optimises the dwell positions of the source, too. Both HIPO
and IPSA inverse optimisation algorithms have been imple-
mented in Elekta BT treatment planning products (Elekta
Brachytherapy, Veendendaal, the Netherlands).
The aim of present study is to analyse the dosimetric
effect of HIPO and IPSA inverse optimisation algorithms
and compare it to the forward optimisation method in high-
dose-rate interstitial BT treatments of breast, cervical and
prostate cancer.
Materials andmethods
At our institute, 38 breast, 47 cervical and 50 prostate can-
cer patients treated with image-guided high-dose-rate inter-
stitial BT were selected for this study.
Postoperative multicatheter breast BT implantation was
performed using a preimplant CT image set. Based on the
postimplant CT, the planning target volume (PTV) and or-
gans at risk were created and the treatment plan was nor-
malised to the basal dose points using the optimal value
of the F-factor and graphical and manual optimisation [11]
were used (Oncentra Brachy v4.5.3, Elekta Brachytherapy,
Veendendaal, the Netherlands). The prescribed dose was
30.1Gy in 7 fractions, twice a day. The detailed descrip-
tion of our treatment method can be found in our previous
publication [14].
BT boost treatment for cervical cancer was delivered
with a combined interstitial intracavitary technique, given
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Fig. 1 Dose distributions using HIPO (hybrid inverse planning optimisation), IPSA (inverse planning simulated annealing) and forward optimi-
sation (FO) in interstitial BT (brachytherapy) of breast (a), cervical (b) and prostate (c) cancer. Red dots: active dwell positions (volumes: red:
PTV [planning target volume]; a green: non-target breast, blue: ipsilateral lung, pink: ribs; b yellow: bladder, green: rectum, violet: sigmoid, pink:
vagina; c yellow: urethra, green: rectum)
1 or 2 fractions weekly. Patients were treated with 4 BT
fractions of 7Gy. Initial and post-teletherapy MRI were
used to determine the number and position of needles in
the ring- or Fletcher-type interstitial applicator. The im-
plantation was transrectal US guided. The delineation of
PTV, bladder, rectum, sigmoid and bowel was performed on
postimplant CT, also using information from post-telether-
apy MRI. During treatment planning, graphical and manual
optimisation was used to achieve an optimal dose distribu-
tion (Oncentra Brachy v4.5.3, Elekta Brachytherapy, Veen-
dendaal, the Netherlands). The detailed description of our
treatment method can be found in our previous publications
[11, 15].
Transrectal US-guided transperineal interstitial prostate
implantation was performed during the 4 weeks of the
EBRT course in a single fraction. After scanning the
prostate with US, a virtual preimplant plan was generated
(Oncentra Prostate v3.1, Elekta Brachytherapy, Veenden-
daal, the Netherlands). The HIPO optimisation method
was used, and the prescribed dose was 10Gy to the whole
prostate gland (V100≥ 95%). Based on this plan, metal
needles were inserted into the prostate through a template
under live US guidance. The optimisation procedure was
used again for the dwell times in the inserted needles to
achieve the final dose distribution. The detailed description
K
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of our treatment method can be found in our previous
publication [16].
Patients were treated with a high-dose-rate (HDR) re-
mote afterloading unit (microSelectron v3, Elekta Brachy-
therapy, Veendendaal, the Netherlands) using an Ir-192
stepping source (type v2) with an initial contained activity
of 370 GBq (reference air kerma rate of 40.7 mGy * m2/h).
The used source step was 2.5mm.
Additional treatment plans were created using HIPO and
IPSA inverse or forward (graphical and manual) optimisa-
tion methods (Fig. 1). To avoid inter-observer variations,
only one physicist who is well-experienced in interstitial
BT made all the plans. With both inverse methods, our
library preset was used first (the used constraints are in Ta-
bles 4 and 5 in the Appendix), then this initial preset was
modified to achieve the optimal dose distribution in each
plan. It has to be noted that inverse algorithms can plan the
optimal catheter distribution only in the Oncentra prostate
planning system. In breast and cervical BT, this feature is
not needed, as the dose planning process is not in real-time.
We defined the catheter positions in a simple manual way
before implantation and did not use this automatic option in
prostate planning neither [11, 14–16]. With FO and HIPO,
active dwell positions were inside or on the surface of the
PTV, while IPSA optimised the source dwell positions and
created active dwells outside the PTV, too. Using HIPO,
the recommended 0.2 value of the dwell time gradient re-
striction was used to modulate the ratio of dwell times of
the adjacent dwell positions [17].
The following dose–volume parameters were used for
quantitative evaluation of the plans:
 V100, V150: the volume of the PTV receiving 100% and
150% of the prescribed dose (%) [18],
 V100, V150, VPTV: absolute volume irradiated by 100% and
150% of the prescribed dose (cc) and the volume of the
PTV,
 D90: the minimum dose delivered to 90% of PTV (Gy)
[19],
 DNR: dose nonuniformity ratio [20, 21]
 DHI: dose homogeneity index [22, 23],
 COIN: conformal index [24],
 D2(x): the minimal dose to the most exposed 2 cc of the
critical organ x (% or Gy) [25],
 D1(x): the minimal dose to the most exposed 1 cc of the
critical organ x (%),
 D0.1(x): the minimal dose to the most exposed 0.1 cc of
the critical organ x (%),
 V50(x): absolute volume to the critical organ x irradiated
by 50% of the prescribed dose (cc), where x is non-tar-
get breast, contralateral breast, skin, lung, heart, blad-
der, rectum, sigmoid or bowel.
The dose–volume parameters do not follow the Gaus-
sian distribution (F-tests were significant for all parame-
ters), so the studied parameters of different treatment plans
were compared with non-parametric Friedman ANOVA and
the LSD post-hoc test (Statistica 12.3, StatSoft, Tulsa, OK,
USA).
Results
Both HIPO and IPSA methods decrease the time of plan-
ning process to FO, from 25 to 15min in breast BT, from 10
to 7min in cervical BT and from 20 to 10min on average
in prostate BT.
IPSA created less dose coverage to the target volume
than HIPO or FO, V100 was 91.7%, 91% and 91.9% for
HIPO, IPSA and FO plans (p= 0.1784) in breast BT, 90.4%,
89.2% and 91% (p= 0.0045) in cervical BT and 97.1%,
96.2% and 97.7% (p= 0.0005) in prostate BT, respectively.
In cervical BT plans, IPSA created larger volumes ir-
radiated by the prescribed dose, V100 was 48.5cc, 59.6cc
and 52.8cc in HIPO, IPSA and FO plans, respectively
(p< 0.001; Fig. 2). The volumes irradiated with high doses
were also larger in IPSA plans: V150 was 26.7cc, 30.3cc
and 28.9cc (p< 0.001), respectively. In the case of breast
and prostate BT plans, there were no significant differences
in these parameters (p= 0.0806 and 0.1038).
In breast BT, all of the plans were appropriately homo-
geneous, DNR was 0.3, 0.3 and 0.29 in HIPO, IPSA and
FO plans, respectively (p= 0.1524). In the case of cervical
BT, IPSA resulted in the most homogeneous plans, with
DNR values of 0.55, 0.50 and 0.54 (p< 0.001), respectively.
HIPO plans were more homogeneous in prostate BT, DHI
was 0.7, 0.6 and 0.6 (p< 0.001).
Fig. 2 The absolute volume irradiated by 100% of the prescribed dose
(V100) using HIPO (hybrid inverse planning optimisation), IPSA (in-
verse planning simulated annealing) and forward optimisation (FO)
methods in interstitial cervical BT (brachytherapy) plans
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Table 1 Dose–volume parameters (mean and range, median) in interstitial breast BT using HIPO (hybrid inverse planning optimisation), IPSA
(inverse planning simulated annealing) and forward optimisation (FO)
Dose–volume parameter HIPO IPSA FO p-value
(ANOVA)b
p-value (post hoc)b
Nr. of needles 13.5 (7–28)a – –
VPTV (cc) 60.2 (26.9–173.6) – –
V100 (%) 91.7 (87.6–96.4) 91.0 (88.8–98.3) 91.9 (90.0–96.0) 0.1784 –
V150 (%) 35.5 (25.8–50.9) 33.2 (16.1–60.3) 36.0 (23.0–42.5) 0.0205 HIPO-IPSA: 0.0409
IPSA-FO: 0.0169
DNR 0.30 (0.25–0.45) 0.30 (0.20–0.50) 0.29 (0.25–0.37) 0.1524 –
COIN 0.72 (0.50–0.80) 0.71 (0.50–0.80) 0.69 (0.49–0.82) 0.0306 HIPO-FO: 0.0339
IPSA-FO: 0.0493
V50(non-target breast, cc) 0.8 (0.3–1.2) 1.3 (0.5–1.7) 0.9 (0.3–1.5) 0.0027 HIPO-IPSA: 0.0245
IPSA-FO: 0.0436
D1(contralateral breast,
%)
1.4 (0.1–1.9) 1.6 (0.6–5.8) 1.5 (0.3–2.3) 0.3146 –
D1(skin, %) 19.8 (8.9–26.8) 21.8 (13.2–38.0) 17.1 (4.2–25.7) 0.0425 HIPO-IPSA: 0.0485
IPSA-FO: 0.0210
D0.1(lung, %) 42.7 (8.5–64.0) 57.4 (8.0–68.7) 44.7 (25.0–74.0) 0.0457 HIPO-IPSA: 0.0024
IPSA-FO: 0.0083
D0.1(heart, %) 22.7 (7.5–49.2) 23.7 (6.1–55.6) 22.9 (8.0–41.0) 0.8984 –
V100, V150 the volume of the PTV (planning target volume) receiving 100% and 150% of the prescribed dose (%), VPTV the volume of the PTV,
DNR dose nonuniformity ratio, COIN conformal index, V50(non-target breast) absolute volume of the non-target breast irradiated by 50% of
the prescribed dose (cc), D1(contralateral breast), D1(skin) the minimal dose of the most exposed 1 cc of the contralateral breast and skin (%),
D0.1(lung), D0.1(heart) the minimal dose of the most exposed 0.1 cc of lung and heart (%)
amedian dose–volume parameters
bFriedman ANOVA and LSD post-hoc test (italicized p-values are significant)
Table 2 Dose–volume parameters (mean and range, median) in interstitial cervical BT (brachytherapy) using HIPO (hybrid inverse planning
optimisation), IPSA (inverse planning simulated annealing) and forward optimisation (FO)
Dose–volume param-
eter
HIPO IPSA FO p-value
(ANOVA)b
p-value (post hoc)b
Nr. of needles 3 (0–6)a – –
VPTV (cc) 35.6 (8.3–100.2) – –
V100 (%) 90.4 (83.2–95) 89.2 (78.9–95.4) 91.0 (84.4–95.6) 0.0045 HIPO-IPSA: 0.0352
IPSA-FO: 0.0214
V150 (%) 59.6 (44.8–67.3) 52.7 (25.8–66.4) 59.0 (44.2–71.4) <0.001 HIPO-IPSA: 0.0053
IPSA-FO: 0.0009
V100 (cc) 48.5 (14.6–118.6) 59.6 (20.7–129.3) 52.8 (16.0–118.4) <0.001 HIPO-IPSA: 0.0015
IPSA-FO: 0.0186
V150 (cc) 26.7 (7.8–68.2) 30.3 (7.4–73.9) 28.9 (8.5–65.8) <0.001 HIPO-IPSA: 0.0017
IPSA-FO: 0.0498
DNR 0.55 (0.44–0.58) 0.50 (0.36–0.57) 0.54 (0.44–0.58) <0.001 HIPO-IPSA: 0.0035
IPSA-FO: 0.0023
COIN 0.60 (0.30–0.73) 0.47 (0.22–0.66) 0.58 (0.34–0.87) <0.001 HIPO-IPSA: 0.0033
IPSA-FO: 0.0043
D2(bladder, Gy) 4.1 (1.5–7.6) 4.3 (1.6–7.7) 4.1 (1.5–7.9) 0.2908 –
D2(rectum, Gy) 2.5 (0.6–6.3) 2.7 (0.6–7.2) 2.6 (0.6–7.9) 0.0009 HIPO-IPSA: 0.0024
IPSA-FO: 0.0083
D2(sigmoid, Gy) 3.2 (1.2–4.5) 3.6 (1.8–6.1) 3.1 (2.0–5.6) <0.001 HIPO-IPSA: 0.0284
IPSA-FO: 0.0059
D2(bowel, Gy) 4.1 (1.8–6.2) 4.6 (2.9–7.4) 4.2 (2.5–5.5) 0.0049 HIPO-IPSA: 0.0301
IPSA-FO: 0.0412
V100, V150 the volume of the PTV (planning target volume) receiving 100% and 150% of the prescribed dose (%), V100, V150, VPTV absolute
volume irradiated by 100% and 150% of the prescribed dose (cc) and the volume of the PTV, DNR dose nonuniformity ratio, COIN conformal
index, D2(bladder), D2(rectum), D2(sigmoid), D2(bowel) the minimal dose of the most exposed 2 cc of the bladder, rectum, sigmoid and bowel
(Gy)
amedian dose-volume parameters
bFriedman ANOVA and LSD post-hoc test (italicized p-values are significant)
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Table 3 Dose–volume parameters (mean and range, median) in HDR (high-dose-rate) interstitial prostate BT (brachytherapy) using HIPO (hybrid
inverse planning optimisation), IPSA (inverse planning simulated annealing) and forward optimisation (FO)
Dose–volume pa-
rameter
HIPO IPSA FO p-value
(ANOVA)b
p-value (post hoc)b
Nr. of needles 18 (16–20)a – –
VPTV (cc) 39.5 (20.1–74.0) – –
V100 (%) 97.1 (89.0–99.0) 96.2 (94.8–98.5) 97.7 (97.0–98.5) 0.0005 HIPO-IPSA: 0.0466
IPSA-FO: 0.0237
V150 (%) 30.1 (22.1–37.0) 38.0 (30.5–56.3) 38.7 (22.0–59.9) <0.001 HIPO-IPSA: 0.0011
HIPO-FO: 0.0008
DHI 0.70 (0.61–0.82) 0.60 (0.44–0.73) 0.61 (0.38–0.77) <0.001 HIPO-IPSA: 0.0024
HIPO-FO: 0.0016
COIN 0.82 (0.73–0.91) 0.70 (0.61–0.72) 0.70 (0.42–0.74) <0.001 HIPO-IPSA: 0.0008
HIPO-FO: 0.0003
D0.1(urethra, %) 113.8
(107.0–119.1)
112.6
(107.4–123.9)
124.6
(113.7–140.3)
<0.001 HIPO-FO: 0.0046
IPSA-FO: 0.0022
D2(rectum, %) 57.4 (46.2–91.0) 59.2 (52.4–72.2) 50.5 (34.8–59.4) <0.001 HIPO-FO: 0.0057
IPSA-FO: 0.0011
V100, V150 the volume of the PTV (planning target volume) receiving 100% and 150% of the prescribed dose (%), VPTV the volume of the PTV,
DHI dose homogeneity index, COIN conformal index, D0.1(urethra) the minimal dose of the most exposed 0.1 cc of the urethra (%), D2(rectum) the
minimal dose of the most exposed 2 cc of the rectum (%)
amedian dose–volume parameters
bFriedman ANOVA and LSD post-hoc test (italicized p-values are significant)
HIPO resulted in more conformal plans, COIN was 0.72,
0.71 and 0.69 (p= 0.0306) in breast BT, 0.6, 0.47 and 0.58
(p< 0.001) in cervical BT and 0.8, 0.7 and 0.7 (p< 0.001)
in prostate BT, respectively.
In breast BT, the dose to the skin and lung was smaller
with HIPO and FO than with IPSA. D1(skin) was 19.8%,
21.8% and 17.1% (p= 0.0425), D0.1(lung) was 42.7%,
Fig. 3 The active dwell positions in the intracavitary applicator and in the interstitial needles in the case of HIPO (hybrid inverse planning
optimisation) and IPSA (inverse planning simulated annealing) optimisation methods. a Red dots: active dwell positions, red dots with yellow
background: active dwell positions inside the target volume. b Red dots: active dwell positions, blue: the interstitial intracavitary applicator
(volumes: red: PTV (planning target volume), yellow: bladder, green: rectum, violet: sigmoid, pink: vagina)
57.4% and 44.7% (p= 0.0457) in HIPO, IPSA and FO
plans, respectively. In cervical BT, the dose to the rectum,
sigmoid and bowel was larger using IPSA. D2(rectum)
was 2.5Gy, 2.7Gy and 2.6Gy (p= 0.0009), D2(sigmoid)
was 3.2Gy, 3.6Gy and 3.1Gy (p< 0.001) and D2(bowel)
was 4.1Gy, 4.6Gy and 4.2Gy (p= 0.0049), respectively. In
prostate BT, the dose to the urethra was higher in FO plans
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than in inverse optimised plans, D0.1(urethra) was 113.8%,
112.6% and 124.6% (p< 0.001), respectively. However, the
rectal dose was smaller using FO, D2(rectum) was 57.4%,
59.2% and 50.5% (p< 0.001), respectively.
The detailed statistical data are in Table 1 for breast,
Table 2 for cervical and Table 3 for prostate BT plans.
Discussion
In several types of cancer, image-guided interstitial brachy-
therapy has no better alternative at present, including high-
tech EBRT as volumetric modulated arc therapy or stereo-
tactic radiation therapy [3]. In spite of the fact that inverse
dose optimisation is one of the hot topics in EBRT, its role
in BT planning has not been evaluated systematically.
Choi et al. compared HIPO and IPSA algorithms for
HDR interstitial tongue BT [6]. They found that these meth-
ods generate similar dosimetric results; however, the total
dwell time with IPSA is 4s longer than that of HIPO. They
used 4–8 needles. Graphical optimisation was needed for
the target coverages to satisfy the clinical goal. Then, the
total dwell time was increased by approximately 10%.
We found superfluous active lengths in interstitial breast
BT cases using the IPSA algorithm. Additionally, despite
that the contour of PTV was not a concave shape, there
were inactive dwell positions between two active positions.
The coverage of the PTV with the prescribed dose was sig-
nificantly lower with IPSA (D90: 101%) than with HIPO
(102%) or FO (102.7%), but this difference is not important
clinically. The volumes irradiated by a high dose (V150)
were larger with HIPO (35.5%) and FO (36.0%) than with
IPSA (33.2%), but the conformality was higher with HIPO
and IPSA than with FO (COIN: 0.72, 0.71, 0.69, respec-
tively). Nevertheless, forward-optimised plans were as ho-
mogeneous as inverse plans, DNR was 0.30 with HIPO,
0.30 using the IPSA algorithm and 0.29 with FO. The dose
to the skin and lung was significantly lower using HIPO and
FO compared to the IPSA method. Overall, FO and HIPO
generated dosimetrically acceptable treatment plans in in-
terstitial breast BT. If all the necessary volumes of interest
are available, HIPO reduces the overall planning time.
Thibault et al. investigated the clinical outcome of in-
verse-planned interstitial gynaecological BT [8]. They used
a perineal template for implantation of a median of 17 nee-
dles and the IPSA algorithm for dose optimisation. They
found that the D90 parameter correlates with local tumour
control. Matias et al. compared the dosimetric results of
FO and HIPO and found that the two methods are dosimet-
rically comparable [26]. Trnková et al. compared forward
and inverse interstitial cervical BT plans using the obsolete
Plato planning system for FO and the special gynaecologic
treatment planning system Oncentra Gyn for inverse plan-
ning [9]. They stated that the conformality is the highest
using HIPO, and the treatment time is less than in FO and
IPSA. IPSA tends to overload the needles and needs addi-
tional contours to work. Our present work shows that IPSA
generated lower-quality treatment plans than FO and HIPO
methods in all the examined dosimetric parameters. IPSA
resulted in longer active lengths and inactive dwell positions
between active ones, as can be seen in Fig. 3. It resulted
in significantly larger volumes irradiated by the prescribed
dose (Fig. 2) and high-dose volumes (V150). In the optimal
case, isodose surface volume correlates with the volume of
the PTV [27]. FO and HIPO generated clinically similar
dosimetric results, but HIPO needs additional adjustment
with FO to reach the dose–volume constraints, especially
in the case of a small number of needles. The number of
needles correlates with the dosimetric quality of the treat-
ment plan, as we showed in our previous study [11].
Pokharel et al. evaluated the HIPO algorithm in HDR
prostate BT [28]. They found that HIPO can provide treat-
ment plans with comparable target coverage to that of FO
with a reduction in dose to the critical structures; how-
ever, HIPO resulted lower target coverage compared to FO.
Panettieri et al. compared IPSA and HIPO [10] and stated
that IPSA generates large dwell times in particular positions
of the catheter, which can be the cause of the resultant lower
homogeneity compared to the HIPO method. Poulin et al.
made a comparison of optimisation algorithms in prostate
BT and found that dose optimisation engines give similar
dosimetric results [29]. Dinkla et al. made a comparison be-
tween graphical, IPSA and HIPO optimisation methods in
HDR/PDR prostate BT [7]. They found that dose–volume
parameters are comparable for all methods, and inverse al-
gorithms resulted in shorter planning time than graphical
optimisation (6.7 vs. 7.6min, on average). We also experi-
enced reduction of the optimisation time with HIPO and
IPSA methods, but the effectiveness of IPSA was sub-
optimal: it generated dosimetrically acceptable plans, but
the value of all the dose–volume parameters was inferior
to using FO or HIPO methods. Additionally, IPSA cre-
ated superfluous active lengths outside the prostate besides
the underdosed prostate region close to rectum. FO and
HIPO resulted in dosimetrically similar plans, but the PTV
dose coverage was higher using FO (D90: 112.2% with
FO vs. 110.4% with HIPO), the high-dose volumes were
smaller with HIPO (V150: 30.1% with HIPO vs. 38.7%
with FO), and HIPO was also more homogeneous (DHI:
0.7 vs. 0.6) and conformal (COIN: 0.8 vs. 0.7, respectively).
The dose to the urethra was lower with HIPO (D0.1: 113.8%
vs. 124.6%), but the rectal dose was higher (D2: 57.4% vs.
50.5%).
Taking every result into account, the IPSA optimisation
method resulted in suboptimal treatment plans and used un-
necessarily longer active lengths in interstitial breast, cervi-
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cal and prostate BT (this superfluous length is usually 1 or
2 dwell positions, so 2.5–5mm). Using the HIPO algorithm,
active dwell positions can be determined before the optimi-
sation of the dwell times in postimplant planning (in breast
and cervical BT), and there is an option to plan the needles
and active dwells inversely during live planning (in prostate
BT) based on our predefined rules. Additionally, with the
dwell time gradient restriction option, HIPO can produce
homogeneous dwell time distribution. In HDR interstitial
breast and prostate BT, HIPO can be recommended for dose
optimisation; however, FO also results in dosimetrically ac-
ceptable plans, but with longer planning time. In the case
of HDR interstitial cervical BT, sometimes a small number
of needles does not give enough opportunities for inverse
optimisation. To achieve the recommended dose coverage
of PTV, additional FO is needed. With FO, isodoses can be
expanded in the areas where organs at risk are not close to
the PTV, while they can be decreased near to these tissues.
Conclusion
In HDR interstitial breast and prostate BT, HIPO results
in comparable dose–volume parameters to FO, but HIPO
plans are more conformal. FO needed more planning time
and more experience of the physicist. In cervical BT, HIPO
produces dosimetrically acceptable plans only if a larger
number of needles are used, and in this case the combination
of FO and HIPO is recommended. The dosimetric quality
of IPSA plans is suboptimal and results in unnecessarily
larger active lengths.
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Appendix
Table 4 Initial dose–volume constraints for the HIPO optimisation algorithms in interstitial breast, cervical and prostate BT
HIPO Region of interest Min value (%) Min weight Max value (%) Max weight
Breast PTV 100 75 150 25
Skin – – 50 40
Ribs – – 50 30
Normal tissue – – 120 5
Cervix HR-CTV 100 80 150 5
Bladder – – 70 10
Rectum – – 50 10
Sigmoid – – 60 10
Normal tissue – – 120 5
Prostate Prostate 100 70 150 5
Urethra – – 120 40
Rectum – – 50 20
Normal tissue – – 120 8
Table 5 Initial dose–volume constraints for the IPSA optimisation algorithms in interstitial breast, cervical and prostate BT
Surface Volume
IPSA Region of
interest
Min value
(%)
Min
weight
Max value
(%)
Max weight Min value
(%)
Min
weight
Max value
(%)
Max
weight
Breast PTV 100 100 150 1 100 100 150 1
Skin – – 40 40 – – – –
Ribs – – 50 30 – – – –
Non-target
breast
– – 120 5 – – 35 100
Cervix HR-CTV 200 100 150 15 200 100 150 10
Bladder – – 70 15 – – 70 15
Rectum – – 50 15 – – 50 15
Sigmoid – – 60 15 – – 60 15
Prostate Prostate 100 5 150 1 100 5 200 0.1
Urethra 100 1 108 3 100 1 108 3
Rectum – – 60 3 – – 60 3
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